The Institute for Clinical and Economic Review (ICER) has canceled the August meeting of the Midwest CEPAC.
The meeting was set to discuss the effectiveness and value of obeticholic acid for the treatment of non-alcoholic steatohepatitis.
“This decision is the result of the Food and Drug Administration recently issuing a Complete Response Letter to Intercept Pharmaceuticals, stating that the current efficacy and safety data was insufficient to support accelerated approval,” ICER says in a press release.
To read the full press release, click here.
